Human Gene Therapy Methods最新文献

{"title":"In Vivo Potency Assay for Adeno-Associated Virus-Based Gene Therapy Vectors Using AAVrh.10 as an Example.","authors":"Bishnu P De,&nbsp;Alvin Chen,&nbsp;Christiana O Salami,&nbsp;Benjamin Van de Graaf,&nbsp;Jonathan B Rosenberg,&nbsp;Odelya E Pagovich,&nbsp;Dolan Sondhi,&nbsp;Ronald G Crystal,&nbsp;Stephen M Kaminsky","doi":"10.1089/hgtb.2017.246","DOIUrl":"https://doi.org/10.1089/hgtb.2017.246","url":null,"abstract":"<p><p>The development of a drug product requires rigorous methods of characterization and quality control to assure drug potency. Gene therapy products, a relatively new strategy for drug design with very few licensed examples, represent a unique challenge for the measure of potency. Unlike traditional drugs, potency for a gene therapeutic is a tally of the measures of multiple steps, including infectivity, transcription, translation, protein modifications, proper localization of the protein product, and protein function. This is particularly challenging for products based on the adeno-associated virus (AAV) platform, which has poor in vitro infectivity, limiting the sensitivity and thus the usefulness of cell-based assays. A rigorous in vivo assay has been established that separately evaluates infection, transcription, and resulting protein levels with specifications for each based on real time polymerase chain reaction (DNA and RNA) and standard protein assays. For an acceptance criterion, an administered vector must have vector DNA, transgene mRNA, and transgene expressed protein each concurrently meet individual specifications or the production lot fails. Using the AAVrh.10 serotype as a model vector and three different transgenes as examples, the assay is based on intravenous administration of the vector to male mice. At 2 weeks, the harvested liver is homogenized and assessed for vector genome levels (to assess for vector delivery), mRNA (to assess vector infectivity and transcription), and protein in the liver or serum (to assess protein expression). For all AAV vectors, the assay is robust and reproducible: vector DNA (linearity 10²-10⁹ copies, coefficient of variation) intra-assay <0.8%, inter-assay <0.5%; mRNA intra-assay <3.3%, inter-assay <3.4%. The reproducibility of the assay for transgene expressed protein is product specific. This in vivo potency assay is a strategy for characterization and a quantitative lot release test, providing a path forward to meet regulatory drug requirements for any AAV gene therapy vectors.</p>","PeriodicalId":13126,"journal":{"name":"Human Gene Therapy Methods","volume":"29 3","pages":"146-155"},"PeriodicalIF":0.0,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/hgtb.2017.246","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36053027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel Vector Construction Based on Alternative Adenovirus Types via Homologous Recombination.","authors":"Wenli Zhang,&nbsp;Jun Fu,&nbsp;Anja Ehrhardt","doi":"10.1089/hgtb.2018.044","DOIUrl":"https://doi.org/10.1089/hgtb.2018.044","url":null,"abstract":"<p><p>Adenoviral vector (AdV) is one of the most used vectors in gene therapy clinical trials. However the therapeutic effect of AdV is limited due to preexisting immunity to the currently used human adenovirus type 5 and pre-decided vector tropism. It is highly demanded to develop novel AdVs originated from other types than adenovirus type 5. Here, we describe a method for direct cloning of adenovirus utilizing linear-linear homologous recombination, followed by rapid adenoviral genome modification via linear-circular homologous recombination. A plasmid bearing chosen adenoviral genome with the desired modification is generated in three weeks, from which a novel AdV can be reconstituted.</p>","PeriodicalId":13126,"journal":{"name":"Human Gene Therapy Methods","volume":"29 3","pages":"124-134"},"PeriodicalIF":0.0,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/hgtb.2018.044","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36094731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficiency and Specificity of Targeted Integration Mediated by the Adeno-Associated Virus Serotype 2 Rep 78 Protein.","authors":"Pingjuan Li,&nbsp;Michael P Marino,&nbsp;Jizhong Zou,&nbsp;Takele Argaw,&nbsp;Michael T Morreale,&nbsp;Brian J Iaffaldano,&nbsp;Jakob Reiser","doi":"10.1089/hgtb.2018.052","DOIUrl":"https://doi.org/10.1089/hgtb.2018.052","url":null,"abstract":"<p><p>The adeno-associated virus serotype 2 (AAV2) Rep 78 protein, a strand-specific endonuclease (nickase) promotes site-specific integration of transgene sequences bearing homology arms corresponding to the AAVS1 safe harbor locus. To investigate the efficiency and specificity of this approach, plasmid-based donor vectors were tested in concert with nuclease encoding vectors, including an engineered version of the AAV2 Rep 78 protein, an AAVS1-specific zinc finger nuclease (ZFN), and the CRISPR-Cas9 components in HEK 293 cells. The Rep 78 and ZFN-based approaches were also compared in HEK 293 cells and in human induced pluripotent stem cells using integrase deficient lentiviral vectors. The targeting efficiencies involving the Rep 78 protein were similar to those involving the AAVS1-specific ZFN, while the targeting specificity for the Rep 78 protein was lower compared to that of the ZFN. It is anticipated that the Rep 78 nickase-based targeting approach may ultimately contribute to the reduction of risks associated with other genome editing approaches involving DNA double-strand breaks.</p>","PeriodicalId":13126,"journal":{"name":"Human Gene Therapy Methods","volume":"29 3","pages":"135-145"},"PeriodicalIF":0.0,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/hgtb.2018.052","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36187670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of humoral, innate, and T-cell immune responses to adeno-associated virus vectors.","authors":"R. Calcedo, Jessica A. Chichester, James M. Wilson","doi":"10.1089/hum.2018.038","DOIUrl":"https://doi.org/10.1089/hum.2018.038","url":null,"abstract":"Adeno-associated virus (AAV)-based gene therapy is being applied to treat a wide array of diseases. Pre-existing host immune responses to AAV and immune responses elicited by AAV vector administration remain a problem that needs to be further studied. Here, we present a series of protocols to assess immune responses before and after AAV vector administration that is applicable to multiple animal models and Phase I clinical trials. More specifically, to evaluate: 1) the humoral immune response, through levels of AAV-neutralizing and binding antibodies; 2) the innate immune response, through the acute induction of inflammatory cytokines; and 3) the T-cell immune response, through the activation of transgene- and vector-specific CD8 and CD4 T cells.","PeriodicalId":13126,"journal":{"name":"Human Gene Therapy Methods","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/hum.2018.038","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46675253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determination of Lentiviral Infectious Titer by a Novel Droplet Digital PCR Method.","authors":"Yu Wang,&nbsp;Svetlana Bergelson,&nbsp;Marina Feschenko","doi":"10.1089/hgtb.2017.198","DOIUrl":"https://doi.org/10.1089/hgtb.2017.198","url":null,"abstract":"<p><p>Lentivirus is one of the best vehicles in delivering exogenous genes for therapeutics. Prior to application, it is very important to determine the infectious titer, which measures only mature virus capable of infecting target cells. Quantitative polymerase chain reaction (PCR) and fluorescence-activated cell sorting are commonly used for determination of infectious titer. This study introduces a new method based on Droplet Digital PCR (ddPCR), a recently developed PCR technology that quantifies the absolute amount of target DNA in the reaction. In this study, the dynamic range, Limit of Quantification (LOQ), and data acceptance criteria for ddPCR are defined against lentiviral sequence. ddPCR performance is also compared to established FACS and qPCR methods. This work not only demonstrates the feasibility of ddPCR in determining lentiviral infectious titer, but provides a detailed method that can be easily adapted by the scientific community.</p>","PeriodicalId":13126,"journal":{"name":"Human Gene Therapy Methods","volume":"29 2","pages":"96-103"},"PeriodicalIF":0.0,"publicationDate":"2018-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/hgtb.2017.198","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35774076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving Lentiviral Transduction of CD34⁺ Hematopoietic Stem and Progenitor Cells.","authors":"Ilona Hauber,&nbsp;Niklas Beschorner,&nbsp;Silke Schrödel,&nbsp;Jan Chemnitz,&nbsp;Nicolaus Kröger,&nbsp;Joachim Hauber,&nbsp;Christian Thirion","doi":"10.1089/hgtb.2017.085","DOIUrl":"https://doi.org/10.1089/hgtb.2017.085","url":null,"abstract":"<p><p>The delivery of therapeutic genes for treatment of inherited or infectious diseases frequently requires lentiviral transduction of CD34⁺ hematopoietic stem and progenitor cells (HSC). Optimized transduction protocols with a therapeutic goal aim to maximize the number of transduction-positive cells while limiting the vector copy number that reach each individual cell. Importantly, the transduced HSC should maintain their \"stem-like\" properties. Here, we analyzed LentiBOOST™ reagent, a membrane-sealing poloxamer, with respect to enhancing lentiviral transduction of CD34⁺ peripheral blood stem cells. We demonstrate that inclusion of LentiBOOST™ in a standard HSC transduction protocol yields high transduction efficiencies while preserving the ability of the transduced HSC to differentiate into various hematopoietic lineages. Thus, LentiBOOST™ reagent can significantly improve lentiviral CD34⁺ HSC transduction protocols with the potential to improve production of gene-modified cell products.</p>","PeriodicalId":13126,"journal":{"name":"Human Gene Therapy Methods","volume":"29 2","pages":"104-113"},"PeriodicalIF":0.0,"publicationDate":"2018-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/hgtb.2017.085","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35988805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of Humoral, Innate, and T-Cell Immune Responses to Adeno-Associated Virus Vectors.","authors":"Roberto Calcedo,&nbsp;Jessica A Chichester,&nbsp;James M Wilson","doi":"10.1089/hgtb.2018.038","DOIUrl":"https://doi.org/10.1089/hgtb.2018.038","url":null,"abstract":"<p><p>Adeno-associated virus (AAV)-based gene therapy is being applied to treat a wide array of diseases. Preexisting host immune responses to AAV and immune responses elicited by AAV vector administration remain a problem that needs to be further studied. Here we present a series of protocols to assess immune responses before and after AAV vector administration that are applicable to multiple animal models and phase 1 clinical trials. More specifically, they may be use to evaluate (1) the humoral immune response, through levels of AAV-neutralizing and binding antibodies; (2) the innate immune response, through the acute induction of inflammatory cytokines; and (3) the T-cell immune response, through the activation of transgene- and vector-specific CD8+ and CD4+ T cells.</p>","PeriodicalId":13126,"journal":{"name":"Human Gene Therapy Methods","volume":" ","pages":"86-95"},"PeriodicalIF":0.0,"publicationDate":"2018-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/hgtb.2018.038","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39965560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Slow Infusion of Recombinant Adeno-Associated Viruses into the Mouse Cerebrospinal Fluid Space.","authors":"Dan Wang,&nbsp;Jia Li,&nbsp;Karen Tran,&nbsp;Daniel R Burt,&nbsp;Li Zhong,&nbsp;Guangping Gao","doi":"10.1089/hgtb.2017.250","DOIUrl":"https://doi.org/10.1089/hgtb.2017.250","url":null,"abstract":"<p><p>Recombinant adeno-associated viruses (rAAVs) are the leading in vivo gene delivery platform, and have been extensively studied in gene therapy targeting various tissues, including the central nervous system (CNS). A single-bolus rAAV injection to the cerebrospinal fluid (CSF) space has been widely used to target the CNS, but it suffers from several drawbacks, such as leakage to peripheral tissues. Here, a protocol is described using an osmotic pump to infuse rAAV slowly into the mouse CSF space. Compared to the single-bolus injection technique, pump infusion can lead to higher CNS transduction and lower transduction in the peripheral tissues.</p>","PeriodicalId":13126,"journal":{"name":"Human Gene Therapy Methods","volume":"29 2","pages":"75-85"},"PeriodicalIF":0.0,"publicationDate":"2018-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/hgtb.2017.250","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35958596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving the Transduction of Bone Marrow-Derived Cells with an Integrase-Defective Lentiviral Vector.","authors":"S Louise Pay,&nbsp;Xiaoping Qi,&nbsp;Jeffrey F Willard,&nbsp;Juliana Godoy,&nbsp;Kavya Sankhavaram,&nbsp;Ranier Horton,&nbsp;Sayak K Mitter,&nbsp;Judith L Quigley,&nbsp;Lung-Ji Chang,&nbsp;Maria B Grant,&nbsp;Michael E Boulton","doi":"10.1089/hgtb.2017.082","DOIUrl":"https://doi.org/10.1089/hgtb.2017.082","url":null,"abstract":"<p><p>In lentiviral vector (LV) applications where transient transgene expression is sufficient, integrase-defective lentiviral vectors (IDLVs) are beneficial for reducing the potential for off-target effects associated with insertional mutagenesis. It was previously demonstrated that human RPE65 mRNA expression from an integrating lentiviral vector (ILV) induces endogenous Rpe65 and Cralbp mRNA expression in murine bone marrow-derived cells (BMDCs), initiating programming of the cells to retinal pigment epithelium (RPE)-like cells. These cells regenerate RPE in retinal degeneration models when injected systemically. As transient expression of RPE65 is sufficient to activate endogenous RPE-associated genes for programming BMDCs, use of an ILV is an unnecessary risk. In this study, an IDLV expressing RPE65 (IDLV3-RPE65) was generated. Transduction with IDLV3-RPE65 is less efficient than the integrating vector (ILV3-RPE65). Therefore, IDLV3-RPE65 transduction was enhanced with a combination of preloading 20 × -concentrated viral supernatant on RetroNectin at a multiplicity of infection of 50 and transduction of BMDCs by low-speed centrifugation. RPE65 mRNA levels increased from ∼12-fold to ∼25-fold (p < 0.05) after modification of the IDLV3-RPE65 transduction protocol, achieving expression similar to the ∼27-fold (p < 0.05) increase observed with ILV3-RPE65. Additionally, the study shows that the same preparation of RetroNectin can be used to coat up to three wells with no reduction in transduction. Critically, IDLV3-RPE65 transduction initiates endogenous Rpe65 mRNA expression in murine BMDCs and Cralbp/CRALBP mRNA in both murine and human BMDCs, similar to expression observed in ILV3-RPE65-transduced cells. Systemic administration of ILV3-RPE65 or IDLV3-RPE65 programmed BMDCs in a mouse model of retinal degeneration is sufficient to retain visual function and reduce retinal degeneration compared to mice receiving no treatment or naïve BMDC. It is concluded that IDLV3-RPE65 is appropriate for programming BMDCs to RPE-like cells.</p>","PeriodicalId":13126,"journal":{"name":"Human Gene Therapy Methods","volume":"29 1","pages":"44-59"},"PeriodicalIF":0.0,"publicationDate":"2018-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/hgtb.2017.082","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35271902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pooled Generation of Lentiviral Tetracycline-Regulated microRNA Embedded Short Hairpin RNA Libraries.","authors":"Felix F Adams,&nbsp;Thomas Hoffmann,&nbsp;Johannes Zuber,&nbsp;Dirk Heckl,&nbsp;Axel Schambach,&nbsp;Adrian Schwarzer","doi":"10.1089/hgtb.2017.182","DOIUrl":"https://doi.org/10.1089/hgtb.2017.182","url":null,"abstract":"<p><p>Short hairpin RNA (shRNA) screens are powerful tools to probe genetic dependencies in loss-of-function studies, such as the identification of therapeutic targets in cancer research. Lentivirally delivered shRNAs embedded in endogenous microRNA contexts (shRNAmiRs) mediate efficient long-term suppression of target genes suitable for numerous experimental contexts and clinical applications. Here, an easy-to-use laboratory protocol is described, covering the design and pooled assembly of focused shRNAmiR libraries into an optimized, Tet-inducible all-in-one lentiviral vector, packaging of viral particles, followed by retrieval and quantification of hairpin sequences after cellular DNA-recovery. Starting from a gene list to the identification of hits, the protocol enables shRNA screens within 6 weeks.</p>","PeriodicalId":13126,"journal":{"name":"Human Gene Therapy Methods","volume":"29 1","pages":"16-29"},"PeriodicalIF":0.0,"publicationDate":"2018-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/hgtb.2017.182","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35730302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}